To overcome the hypoglycemia risk and potentially mitigate the durability problems of systemic glucokinase activations, efforts have been undertaken to investigate liver specific activation of glucokinase as a possible therapeutic strategy [13]–[15]. Here, GCK is linked to Hypoglycemia.